Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: A double-blind, randomized, placebo-controlled study

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 574-581

  Locatelli, Francesco ^a   Dimkovic, Nada ^b   Pontoriero, Giuseppe ^a   Spasovski, Goce ^c   Pljesa, Stevo ^d   Kostic, Svetislav ^e   Manning, Allan ^f   Sano, Hiroyuki ^g   Nakajima, Shigekazu ^g  

^a A MANZONI HOSPITAL   (Italy)

^b ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

^c SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^d Clinical Hospital Center Zemun   (Serbia)

^e Clinical Centre Nis Institute for Nephrology and Haemodialysis   (Serbia)

^f Mitsubishi Pharma Europe Ltd   (United Kingdom)

^g MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Calcium; Calcium phosphorus product (Ca P); Cholesterol; Chronic kidney disease (CKD) stage 5; Dyslipidaemia; Hyperphosphataemia

Indexed keywords

CHOLESTEROL; COLESTILAN; PHOSPHATE; PHOSPHORUS; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AGED; BILE ACIDS AND SALTS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; YOUNG ADULT;

EID: 75649152827     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp445     Document Type: Article

References (29)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
2. Lach F, Yudd M. The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998; 13(Suppl 3): 57-61
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end stage renal failure who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
4. Block GA, Port FK. Re-evaluation of risks associated with hyper-phosphataemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
5. National Kidney Foundation. K/DOQI Clinical Practice guidelines for bone metabolism and disease in chronic kidney disease. Available at: www.kidney.org/professionals/kdoqi/guidelines-bone/index.htm
6. Locatelli F, Cannata-And́ia JB, Drüeke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723-731
7. Locatelli F. The need for better control of secondary hyperparathy-roidism. Nephrol Dial Transplant 2004; 19(Suppl 5): v15-v19
8. Al Aly Z, Gonzalez EA, Martin KJ et al. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004; 24: 422-426
9. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 2005; 67: 1179-1187
10. Guérin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
11. London GM, Guérin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
12. Coburn JW, Norris KC, Nebecker HG. Osteomalacia and bone disease arising from aluminium. Semin Nephrol 1986; 6: 68-89
13. Goodman WG, Leite Duarte ME. Aluminium: effect on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolyte Metab 1991; 17: 221-232
14. McGonigle RJ, Parsons V. Aluminium-induced anaemia in haemodialysis patients. Nephron 1985; 39: 1-9
15. Locatelli F, Pozzoni P, Tentori F et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant 2003; 18(Suppl 7): vii2-vii9
16. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
17. Bleyer AJ, Burke S, Dillon M et al. A comparison of a calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphataemia in haemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
18. Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphatemia in hemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005; 20: 424-430
19. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161
20. Levin NW, Hoenich NA. Consequences of hyperphosphataemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 2001; 10: 563-568
21. Goodman W. Vascular calcification in chronic renal failure. Lancet 2001; 358: 1115-1116
22. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 172: 1130-1137
23. St Peter WL, Liu J, Weinhandl E et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51: 445-454
24. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyper-phosphataemia in haemodialysis patients: the Calcium Acetate Re-nagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914-1926
25. Brunzell JD, Albers JJ, Haas LB et al. Prevalence of serum lipid abnormalities in chronic haemodialysis. Metabolism 1977; 26: 903-910
26. Mitsuka M, Hashimoto M, Takizawa T et al. Hypolipidemic effects of MCI-196, a novel anion exchange resin in rabbits. Japan Pharmacol Ther 1996; 24: S585-S594
27. Qunibi WY. Dyslipidaemia and progress of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int 2005; 67(Suppl 95): S43-S50
28. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 (Pubitemid 41058323)
29. McIntyre CW, Patel V, Taylor GS et al. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1643-1648